MEI Pharma Gets $27.5M In PIPE

San Diego-based MEI Pharma, a publicly traded developer of oncology drugs, said today that it has completed a $27.5M private placement. The new funding was led by Vivo Ventures and New Leaf Venture Partners. MEI Pharma said the new funding will go to advance clinical development of its lead drug candidate, which is an oral histone deacetylase (HDAC) inhibitor. That compound is being used to treat myelodysplastic syndrome (MDS), acute myeloid leukemia and myelofibrosis. More information »